Earnings Call · Q4 FY2024·2025-03-18

Q4 24EPS +27.88%·Rev n/aQ3 24EPS +21.24%·Rev n/aQ2 24EPS -8.18%·Rev n/aQ1 24EPS -32.32%·Rev n/a⚠ consensus missing

INOVIO PHARMACEUTICALS, INC. INO

Jennie Willson — Investor Relations

Jacqui Shea — President and Chief Executive Officer

Mike Sumner — Chief Medical Officer

Steve Egge — Commercial/Market Access Executive

Peter Kies — Chief Financial Officer

−0.5%1d on move date+0.6% vs SPY3d−8.1%5d−10.9%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more INO calls or request research access.

More INO calls Browse calls Request research access